

Marta Ruiz Egozcue

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6586053/publications.pdf>

Version: 2024-02-01

14
papers

557
citations

1040056

9
h-index

1125743

13
g-index

14
all docs

14
docs citations

14
times ranked

1000
citing authors

#	ARTICLE	IF	CITATIONS
1	PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity. <i>Cell Reports</i> , 2017, 20, 1818-1829.	6.4	220
2	Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 379-393.	4.2	100
3	Inhibition of FOXP3/NFAT Interaction Enhances T Cell Function after TCR Stimulation. <i>Journal of Immunology</i> , 2015, 195, 3180-3189.	0.8	44
4	IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination. <i>Oncotarget</i> , 2017, 8, 2659-2671.	1.8	41
5	ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor Immunity. <i>Molecular Therapy</i> , 2019, 27, 1878-1891.	8.2	38
6	Blockage of FOXP3 transcription factor dimerization and FOXP3/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor. <i>Oncotarget</i> , 2017, 8, 71709-71724.	1.8	27
7	Vaccine-induced but not tumor-derived Interleukin-10 dictates the efficacy of Interleukin-10 blockade in therapeutic vaccination. <i>Oncolmmunology</i> , 2016, 5, e1075113.	4.6	20
8	Cold-Inducible RNA Binding Protein as a Vaccination Platform to Enhance Immunotherapeutic Responses against Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 3397.	3.7	17
9	Neoantigens as potential vaccines in hepatocellular carcinoma. , 2022, 10, e003978.		16
10	The Toll like receptor 4 ligand cold-inducible RNA-binding protein as vaccination platform against cancer. <i>Oncolmmunology</i> , 2018, 7, e1409321.	4.6	15
11	Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses. <i>Emerging Microbes and Infections</i> , 2021, 10, 1931-1946.	6.5	11
12	Helper cell-independent antitumor activity of potent CD8+T cell epitope peptide vaccines is dependent upon CD40L. <i>Oncolmmunology</i> , 2013, 2, e27009.	4.6	3
13	Searching for Peptide Inhibitors of T Regulatory Cell Activity by Targeting Specific Domains of FOXP3 Transcription Factor. <i>Biomedicines</i> , 2021, 9, 197.	3.2	3
14	Engineered promiscuous T helper peptides for the induction of immune responses. <i>Molecular Immunology</i> , 2007, 44, 2205-2212.	2.2	2